Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients-Reference-Cited by-同舟云学术

Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

Published:2012-12-11 Issue:2 Volume:15 Page:316-323
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Nyholm Dag,Odin Per,Johansson Anders,Chatamra Krai,Locke Charles,Dutta Sandeep,Othman Ahmed A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-012-9439-1.pdf

Reference43 articles.

1. Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62(1):1–8.

2. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord. 2004;19(9):997–1005.

3. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat disord. 2007;13(suppl):S13–7.

4. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Parkinsonism Relat disord. 2009;15 suppl 1:S9–S15.

5. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677–87.

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surface-Enhanced Raman Scattering Nanosensing and Imaging in Neuroscience;ACS Nano;2024-08-01

2. Oral Levodopa Stimulates Copeptin Secretion in Children and Adolescents with Intact Posterior Pituitary Function;Endocrine Practice;2024-08

3. Levodopa: From Biological Significance to Continuous Monitoring;ACS Sensors;2024-07-24

4. Effects of Continuous Dopaminergic Stimulation on Parkinson’s Disease Gait: A Longitudinal Prospective Study with Levodopa Intestinal Gel Infusion;Journal of Parkinson's Disease;2024-06-04

5. Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel;Pharmacology Research & Perspectives;2024-04